Recent share performance and business context

Rhythm Pharmaceuticals (RYTM) has drawn investor attention after a recent period in which the stock fell 7% over the past month but gained about 21% over the past 3 months.

The company focuses on treatments for rare neuroendocrine diseases, with commercial revenue of about US$217.2 million and a reported net loss of roughly US$207.8 million, which keeps profitability in clear focus for shareholders.

At the current share price of US$102.10, Rhythm Pharmaceuticals has delivered a 1 year total shareholder return of 19.16%, alongside a very large 5 year total shareholder return. The 1 day share price return of 0.55% and 30 day share price return of 7.05% indicate that some recent momentum has faded following a strong 90 day share price return of 21.29%.

If Rhythm Pharmaceuticals has you interested in healthcare and rare-disease exposure, it can be useful to compare it with other ideas in similar areas using our screener for 40 healthcare AI stocks

Rhythm Pharmaceuticals has pulled back over the past month after a strong 90 day run. This puts a spotlight on one core decision: does buying now offer reasonable value, or does it make more sense to wait for a cheaper entry?

Most Popular Narrative: 26.8% Undervalued

The most followed Rhythm Pharmaceuticals valuation narrative places fair value at about $139.47 per share versus the recent $102.10 close. This frames the stock as materially undervalued and heavily tied to the outlook for setmelanotide in rare obesity indications.

Upcoming potential regulatory approvals and launches for setmelanotide (IMCIVREE) in new indications like acquired hypothalamic obesity and Prader-Willi syndrome, alongside expansion into younger age groups, are set to materially grow Rhythm's commercial opportunity and topline over the next several years.

Want to understand why this narrative supports such a high fair value for Rhythm Pharmaceuticals? It leans on expectations for rapid revenue expansion, a sharp swing toward profitability, and a rich future earnings multiple that is uncommon for most biotechs.

Result: Fair Value of $139.47 (UNDERVALUED)

However, Rhythm Pharmaceuticals still faces meaningful risks, including ongoing operating losses and heavy reliance on setmelanotide, which could challenge the 26.8% undervaluation narrative.

Another View: Rhythm Pharmaceuticals Through a P/S Lens

The earlier fair value of $139.47 for Rhythm Pharmaceuticals leans heavily on future earnings and cash flows. On a simple revenue multiple, though, the picture looks very different, with the stock trading on a P/S of 32.2x versus about 10.8x for the US Biotechs industry and an estimated fair ratio of 19.8x. That gap suggests investors are already paying a rich price for each dollar of current sales, so how comfortable are you with that trade off between upside narrative and valuation risk?

Next Steps

With Rhythm Pharmaceuticals presenting a mix of upside narratives and valuation questions, it can be helpful to review the underlying data directly and move quickly to form your own conviction. To see what investors view as the key positives right now, take a closer look at the 3 key rewards.

Looking for more investment ideas beyond Rhythm Pharmaceuticals?

If Rhythm Pharmaceuticals has sharpened your focus on what matters, do not stop here. Use the Simply Wall St screener to spot fresh opportunities that fit your style.

• Target potential mispricings by scanning for companies that combine quality with value through our 50 high quality undervalued stocks.
• Strengthen your income focus by reviewing stocks that aim for higher yields with the 9 dividend fortresses.
• Prioritize resilience by filtering for companies with sound finances using the solid balance sheet and fundamentals stocks screener (49 results).

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.